Status:
COMPLETED
Deep Learning Model for the Prediction of Post-LT HCC Recurrence
Lead Sponsor:
European Hepatocellular Cancer Liver Transplant Group
Conditions:
Liver Transplant Disorder
Liver Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Identifying patients at high risk for recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) represents a challenging issue. The present study aims to develop and validate an ac...
Detailed Description
In 1996, the introduction of the Milan criteria (MC) strongly modified the selection process of hepatocellular cancer (HCC) patients waiting for liver transplantation (LT). Many attempts to widen MC h...
Eligibility Criteria
Inclusion
- Consecutive adult (≥18 years) patients enlisted and transplanted with the primary diagnosis of HCC during the period 2000-2018.
Exclusion
- Patients with HCC diagnosed only at pathological examination (incidental HCC)
- Patients with mixed hepatocellular-cholangiocellular cancer misdiagnosed as HCC
- Patients with cholangiocellular cancer misdiagnosed as HCC
- Patients dying early after LT (≤ one month)
Key Trial Info
Start Date :
January 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 15 2022
Estimated Enrollment :
4026 Patients enrolled
Trial Details
Trial ID
NCT05200195
Start Date
January 15 2020
End Date
March 15 2022
Last Update
June 30 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Quirino Lai
Rome, RM, Italy, 00151